Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.
作者信息
Nellan Anandani, McCully Cynthia M Lester, Cruz Garcia Rafael, Jayaprakash Nalini, Widemann Brigitte C, Lee Daniel W, Warren Katherine E
机构信息
Department of Pediatrics, University of Colorado, Denver Anschutz Medical Center, Aurora, CO.
Morgan Adams Foundation Pediatric Brain Tumor Research Program, Children's Hospital Colorado, Aurora, CO.
出版信息
Blood. 2018 Aug 9;132(6):662-666. doi: 10.1182/blood-2018-05-846428. Epub 2018 Jun 28.
Abstract
摘要
相似文献
1
Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques.与静脉注射相比，恒河猴脑脊液注射托珠单抗后中枢神经系统暴露情况有所改善。
Blood. 2018 Aug 9;132(6):662-666. doi: 10.1182/blood-2018-05-846428. Epub 2018 Jun 28.
2
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20.单剂量皮下注射托珠单抗联合或不联合重组人透明质酸酶PH20的药代动力学和药效学
Int J Clin Pharmacol Ther. 2013 Jul;51(7):537-48. doi: 10.5414/CP201847.
3
Pharmacokinetics of tramadol following intravenous and oral administration in male rhesus macaques (Macaca mulatta).曲马多在雄性恒河猴（猕猴）静脉注射和口服给药后的药代动力学
J Vet Pharmacol Ther. 2015 Aug;38(4):375-82. doi: 10.1111/jvp.12194. Epub 2014 Dec 9.
4
Plasma and CSF oxytocin levels after intranasal and intravenous oxytocin in awake macaques.清醒猕猴经鼻内和静脉注射催产素后的血浆和脑脊液催产素水平。
Psychoneuroendocrinology. 2016 Apr;66:185-94. doi: 10.1016/j.psyneuen.2016.01.014. Epub 2016 Jan 18.
5
Preclinical pharmacokinetics of a recombinant humanized rabbit anti-VEGF monoclonal antibody in rabbits and monkeys.兔和猴体内重组人源化兔抗 VEGF 单克隆抗体的临床前药代动力学研究。
Toxicol Lett. 2018 Aug;292:73-77. doi: 10.1016/j.toxlet.2018.04.031. Epub 2018 Apr 27.
6
Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA.来自两项随机对照试验SUMMACTA和BREVACTA的类风湿关节炎患者皮下注射托珠单抗的药代动力学和药效学分析
J Clin Pharmacol. 2017 Apr;57(4):459-468. doi: 10.1002/jcph.826. Epub 2016 Nov 17.
7
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.奥洛昔单抗（一种抗 IL-6 单克隆抗体）在健康男性志愿者中的安全性和药代动力学：一项随机的 I 期研究。
Clin Pharmacol Drug Dev. 2014 Sep;3(5):388-95. doi: 10.1002/cpdd.121. Epub 2014 May 26.
8
Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.静脉注射托珠单抗在类风湿关节炎中的固定剂量。群体药代动力学分析的结果。
Br J Clin Pharmacol. 2018 Apr;84(4):716-725. doi: 10.1111/bcp.13500. Epub 2018 Feb 7.
9
Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.恒河猴慢性给予穿透血脑屏障的人源化抗人转铁蛋白受体单克隆抗体后的血脑屏障转运、血浆药代动力学和神经病理学。
Mol Pharm. 2018 Nov 5;15(11):5207-5216. doi: 10.1021/acs.molpharmaceut.8b00730. Epub 2018 Sep 27.
10
Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301].三种部位单次皮下注射依洛尤单抗（一种针对前蛋白转化酶枯草溶菌素 9 的单克隆抗体）的药代动力学和药效学研究 [NCT 02043301]。
Cardiovasc Ther. 2017 Oct;35(5). doi: 10.1111/1755-5922.12278.
引用本文的文献
1
Successful Treatment of Polyarteritis Nodosa With Multifocal Intracranial and Mesenteric Stenoses Using Endovascular Stenting and Tocilizumab.采用血管内支架置入术及托珠单抗成功治疗伴有多灶性颅内和肠系膜狭窄的结节性多动脉炎
Cureus. 2025 Aug 8;17(8):e89607. doi: 10.7759/cureus.89607. eCollection 2025 Aug.
2
Cytokine release syndrome in solid tumors.实体瘤中的细胞因子释放综合征
Cancer. 2025 Sep 1;131(17):e70069. doi: 10.1002/cncr.70069.
3
Toxicities associated with lymphoma-targeting bispecific antibodies-a review.与淋巴瘤靶向双特异性抗体相关的毒性——综述
Front Med (Lausanne). 2025 Jul 2;12:1582975. doi: 10.3389/fmed.2025.1582975. eCollection 2025.
4
Current Advances and Challenges in CAR-T Therapy for Hematological and Solid Tumors.嵌合抗原受体T细胞（CAR-T）疗法在血液系统肿瘤和实体瘤治疗中的当前进展与挑战
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
5
Novel strategies to manage CAR-T cell toxicity.管理嵌合抗原受体T细胞毒性的新策略。
Nat Rev Drug Discov. 2025 May;24(5):379-397. doi: 10.1038/s41573-024-01100-5. Epub 2025 Feb 3.
6
Cancer Therapy-Induced Encephalitis.癌症治疗诱发的脑炎
Cancers (Basel). 2024 Oct 23;16(21):3571. doi: 10.3390/cancers16213571.
7
CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview.嵌合抗原受体 T 细胞疗法治疗系统性红斑狼疮：全面综述。
Int J Mol Sci. 2024 Sep 29;25(19):10511. doi: 10.3390/ijms251910511.
8
Checkpoint for Considering Interleukin-6 as a Potential Target to Mitigate Secondary Brain Injury after Cardiac Arrest.将白细胞介素-6视为减轻心脏骤停后继发性脑损伤潜在靶点的考量要点。
Brain Sci. 2024 Jul 31;14(8):779. doi: 10.3390/brainsci14080779.
9
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.乘风破浪：CAR-T 细胞疗法中细胞因子相关毒性的管理。
Semin Immunopathol. 2024 Jul 16;46(3-4):5. doi: 10.1007/s00281-024-01013-w.
10
Outcome of Tocilizumab Treatment in Febrile Neutropenic Children with Severe Sepsis/Septic Shock in a Single-Center Retrospective Case Series.单中心回顾性病例系列研究：托珠单抗治疗发热性中性粒细胞减少症合并严重脓毒症/脓毒性休克儿童的疗效
Cancers (Basel). 2024 Apr 16;16(8):1512. doi: 10.3390/cancers16081512.
本文引用的文献
1
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.嵌合抗原受体 T 细胞介导的非人灵长类动物神经毒性。
Cancer Discov. 2018 Jun;8(6):750-763. doi: 10.1158/2159-8290.CD-17-1368. Epub 2018 Mar 21.
2
Interleukin 6-Mediated Endothelial Barrier Disturbances Can Be Attenuated by Blockade of the IL6 Receptor Expressed in Brain Microvascular Endothelial Cells.白细胞介素 6 介导体血管内皮屏障紊乱可通过阻断脑微血管内皮细胞表达的白细胞介素 6 受体得到缓解。
Transl Stroke Res. 2018 Dec;9(6):631-642. doi: 10.1007/s12975-018-0614-2. Epub 2018 Feb 10.
3
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell-Associated Neurotoxicity.中枢神经系统内皮细胞激活成为 CAR T 细胞相关神经毒性的驱动因素。
Cancer Discov. 2017 Dec;7(12):1371-1373. doi: 10.1158/2159-8290.CD-17-1084.
4
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.嵌合抗原受体 T 细胞过继免疫治疗后神经毒性中的血管内皮细胞激活和血脑屏障破坏。
Cancer Discov. 2017 Dec;7(12):1404-1419. doi: 10.1158/2159-8290.CD-17-0698. Epub 2017 Oct 12.
5
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.在非人类灵长类动物模型中，经鼻给药后选定化疗药物的血浆和脑脊液药代动力学。
J Neurooncol. 2017 May;132(3):401-407. doi: 10.1007/s11060-017-2388-x. Epub 2017 Mar 13.
6
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.急性淋巴细胞白血病新型疗法引发的细胞因子释放综合征
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):567-572. doi: 10.1182/asheducation-2016.1.567.
7
8
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy.CD19导向的嵌合抗原受体修饰T细胞疗法中的主要脑源性细胞因子释放综合征
J Hematol Oncol. 2016 Aug 15;9(1):70. doi: 10.1186/s13045-016-0299-5.
9
Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.血清托珠单抗谷浓度可用于监测类风湿关节炎患者的全身白细胞介素-6受体阻断：一项前瞻性观察队列研究。
Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.
10
Development of a cerebrospinal fluid lateral reservoir model in rhesus monkeys (Macaca mulatta).恒河猴（猕猴）脑脊液外侧储器模型的建立。
Comp Med. 2015 Feb;65(1):77-82.
Zotero 插件